New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
04:55 EDTBAX, BAX, BAX, BAX, NVDQ, NVDQ, NVDQ, NVDQ, RTIX, RTIX, RTIX, RTIX, SYK, SYK, SYK, SYK, TFX, TFX, TFX, TFX, GIVN, GIVN, GIVN, GIVN, EW, EW, EW, EW, ETRM, ETRM, ETRM, ETRM, ECIA, ECIA, ECIA, ECIA, COV, COV, COV, COV, CNMD, CNMD, CNMD, CNMD, CFN, CFN, CFN, CFN, CADX, CADX, CADX, CADX, BSX, BSX, BSX, BSX, NPSP, NPSP, NPSP, NPSPSociety of American Gastrointestinal & Endoscopic Surgeons holds annual meeting
2014 Annual Meeting of SAGES is being held in Salt Lake City, Utah on April 2-5.
News For BAX;BSX;CADX;CFN;CNMD;COV;ECIA;ETRM;EW;GIVN;TFX;SYK;RTIX;NVDQ;NPSP From The Last 14 Days
Check below for free stories on BAX;BSX;CADX;CFN;CNMD;COV;ECIA;ETRM;EW;GIVN;TFX;SYK;RTIX;NVDQ;NPSP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 7, 2014
15:31 EDTCFNNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include CBS (CBS), consensus 72c; Consolidated Edison (ED), consensus 54c; Monster Beverage (MNST), consensus 75c; News Corporation (NWSA), consensus 3c; NVIDIA (NVDA), consensus 20c; Computer Sciences (CSC), consensus 94c; CareFusion (CFN), consensus 72c;DeVry Education (DV), consensus 67c; Salix Pharmaceuticals (SLXP), consensus $1.72; Federal Realty (FRT), consensus $1.21; SolarCity (SCTY), consensus (99c); Medivation (MDVN), consensus 24c; Sprouts Farmers Market (SFM), consensus 18c; Alnylam Pharmaceuticals (ALNY), consensus (56c); Lions Gate (LGF), consensus 17c; Mercadolibre (MELI), consensus 56c; Post Holdings (POST), consensus 27c; Assured Guaranty (AGO), consensus 35c; Great Plains Energy (GXP), consensus 41c; Air Lease (AL), consensus 52c; Ubiquiti Networks (UBNT), consensus 51c; SemGroup (SEMG), consensus 35c.
13:24 EDTSYKStryker upcoming analyst day may be catalyst for shares, says Argus
Argus believes Stryker is well positioned to post stronger sales and earnings in the second half of the year as new products launch and surgical volume rebounds. The firm thinks the company's analyst day on September 17 could be a catalyst for the shares and it maintains its Buy rating and $102 price target on the stock.
10:51 EDTCOVOptions with increasing implied volatility
Subscribe for More Information
09:03 EDTBAXBaxter opens biologics facility in Singapore
Baxter International announced the formal opening of its first advanced recombinant biologic facility in Singapore, and expansion plans for a new recombinant protein processing suite. The current suite supports the processing of ADVATE.The second suite will initially process RIXUBIS, a recombinant factor IX protein for the treatment of adults with hemophilia B and, when operational, will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment BAX 855 upon regulatory approval. The Singapore facility received regulatory approval from the European Medicines Agency in January 2014 for the production of ADVATE2. This allows the facility to process and supply ADVATE to the European Union, Iceland and Norway. The biologics facility in Singapore currently employs more than 400 production staff and expects to reach 450 by 2015 to support the second processing suite.
08:58 EDTCOVMedtronic receives request of additional info from FTC for Covidien acquisition
On August 6, 2014, in connection with the FTC review of the pending acquisition by Medtronic (MDT) of Covidien (COV), which will result in both Medtronic and Covidien becoming wholly owned subsidiaries of Medtronic, Medtronic received a request for additional information and documentary material from the FTC. Issuance of the second request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after Medtronic and Covidien have substantially complied with the second request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. Medtronic and Covidien intend to cooperate fully with the FTC and continue to expect the Transaction to be completed in the fourth calendar quarter of 2014 or early 2015.
08:10 EDTNPSPNPS Pharmaceuticals management to meet with Leerink
Subscribe for More Information
07:17 EDTETRMEnteroMedics reports Q2 EPS (11c), consensus (10c)
Reports Q2 revenue $0.00, consensus $100.00K.
06:42 EDTCOVObama to look to limit inversion deals, Politico says
Subscribe for More Information
August 6, 2014
18:15 EDTBSXBoston Scientific discloses subpoenas in 10-Q filing
Subscribe for More Information
16:51 EDTNPSPNPS Pharmaceuticals says on track to meet FY14 $100M-$110M revenue view
The company continues to expect FY14 operating expenses, excluding the impact of share-based compensation and cost of goods sold, to be between $180M-$200M.
16:48 EDTNPSPNPS Pharmaceuticals reports Q2 EPS 2c, consensus 0c
Reports Q2 revenue $56.1M, consensus $53.06M.
13:42 EDTCOVMedtronic says approval for Covidien deal 'progressing'
Subscribe for More Information
13:39 EDTCOVMedtronic CEO says Covidien deal should close end of year, early next
Subscribe for More Information
13:38 EDTCOVMedtronic CEO says 'progressing' in Covidien deal approval process
Subscribe for More Information
12:59 EDTCOVCovidien drops as Treasury explores ways to stymie inversions
Shares of medical device and drug maker Covidien (COV) are falling after multiple media outlets reported that the Treasury Department is looking into ways of curtailing tax inversion deals. Covidien has agreed to be acquired by Medtronic (MDT) in a tax inversion deal. BACKGROUND: Tax inversions refer to an acquisition of one company, usually officially based in a country in Europe or elsewhere, by a U.S. company, following which the acquiring company becomes domiciled in the same country as the company that it bought. The switch has the potential to significantly lower the acquiring company's tax rate. WHAT'S NEW: The Treasury Department is looking at options that would enable the Obama administration to curtail inversion deals without authorization from Congress, multiple media outlets reported last night and today. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that he believes that Medtronic would buy Covidien even if the transaction cannot be done as an inversion. At a conference in June, Medtronic CFO Gary Ellis said that his company would "do the deal whether it's an inversion or not inversion," Biegelsen stated. If no inversion is possible, Medtronic would respond by using less of its stock and more debt to fund the transaction, the analyst believes. Such a change would actually cause Medtronic's cash earnings per share to be higher in the first and second year after the deal than under the current structure, the analyst indicated. He kept an Outperform rating on Medtronic. PRICE ACTION: In early afternoon trading, Covidien dropped 2% to $84.50 and Medtronic fell 1% to $61.50. Meanwhile, drug maker Shire (SHPG), which has agreed to merge with its peer AbbVie (ABBV) in a tax inversion deal, is falling 4% to $236.
12:20 EDTCOVMedtronic remains committed to Covidien deal, says Wells Fargo
Following recent conversations with the company, Wells Fargo believes Medtronic (MDT) remains committed to the acquisition Covidien (COV), even if the deal can't be structured as an inversion. The firm notes that at its conference in June, Medtronic CFO Gary Ellis stated that "from Medtronic's perspective, we would do the deal whether it's an inversion or not inversion." Wells adds, however, that Medtronic would likely try to renegotiate the terms of the deal if an inversion is not possible.
07:32 EDTNVDQNovadaq revenue growth could accelerate, says Stifel
Subscribe for More Information
07:20 EDTNVDQNovadaq shares should be bought after miss, says JMP Securities
After Novadaq reported weaker than expected Q2 results, JMP Securities is encouraged by the company's focus on clinical trials and remains upbeat about the clinical value of its SPY fluorescence technology. Consequently, the firm continues to recommend buying the shares.
06:41 EDTCOVObama administration may restrict inversion tax benefits, NY Times says
Subscribe for More Information
06:23 EDTEWMitsubishi UFJ to hold a conference
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use